sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Selexipag

Medicine · Prostacyclin Receptor Agonist

Selexipag

UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I): In adults to delay disease progression and reduce the risk of hospitalization for PAH.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • In pediatric patients aged 2 years and older.
  • UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH.
Do not take if
Hypersensitivity to the active substance or to any of the excipients.

What it is used for

UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I): In adults to delay disease progression and reduce the risk of hospitalization for PAH. In pediatric patients aged 2 years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH.

Pulmonary Arterial Hypertension Adult Patients UPTRAVI is indicated for the treatment of pulmonary arterial hypertension in adults (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness of UPTRAVI tablets was established in a long-term study in adult PAH patients with WHO Functional Class II–III symptoms.

Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), PAH associated with congenital heart disease with repaired shunts (10%). Pediatric Patients UPTRAVI is indicated for the treatment of PAH (WHO Group I) in pediatric patients aged two years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH.

Who should not take it

Hypersensitivity to the active substance or to any of the excipients.

Concomitant use of strong inhibitors of CYP2C8 (e.g., gemfibrozil).

Storing it

Store at 20 °C to 25 °C (68 °F to 77 °F). Excursions are permitted between 15 °C and 30 °C (59 °F and 86 °F).

Recommended storage for UPTRAVI 100 mcg and 150 mcg tablets: Store and dispense in the original package to protect from moisture.

Keep out of reach of children.

UPTRAVI ® (selexipag) for injection, for intravenous use, is supplied in a 10 mL Type I glass vial closed by a stopper and sealed with an aluminum flip-off button, containing 1,800 mcg of selexipag [NDC 66215-718-01].

UPTRAVI ® (selexipag) for injection is available in cartons containing 1 single-dose vial.

Storage conditions for UPTRAVI for injection: Store the original carton containing glass vial in a refrigerator at 2 °C to 8 °C (36 ºF to 46 ºF) until use in order to protect from light.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Selexipag; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/selexipag

APA 7th

sofidex. (2026, August 3). Selexipag. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/selexipag

AMA 11th

Selexipag. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/selexipag

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.